This article was originally published here<\/p>\n
J Sex Med. 2020 Oct 9:S1743-6095(20)30936-X. doi: 10.1016\/j.jsxm.2020.09.013. Online ahead of print.<\/p>\n
ABSTRACT<\/p>\n
BACKGROUND: Men who contract coronavirus disease 2019 (COVID-19) appear to have worse clinical outcomes compared with women which raises the possibility of androgen-dependent effects.<\/p>\n
AIM: We sought to determine if testosterone replacement therapy (TRT) is associated with worse clinical outcomes.<\/p>\n
METHODS: Through a retrospective chart review, we identified 32 men diagnosed with COVID-19 and on TRT. They were propensity score matched to 63 men diagnosed with COVID-19 and not on TRT. Data regarding comorbidities and endpoints such as hospital admission, intensive care unit admission, ventilator utilization, thromboembolic events, and death were extracted. Chi-square and Kruskal-Wallis tests examined differences in categorical and continuous variables, respectively. Logistic regression analysis tested the relationship between TRT status and the study endpoints.<\/p>\n
RESULTS: There were no statistically significant differences between the 2 groups, and TRT was not a predictor of any of the endpoints on multivariate analysis.<\/p>\n
CONCLUSION: These results suggest that TRT is not associated with a worse clinical outcome in men diagnosed with COVID-19. Rambhatla A, Bronkema CJ, Corsi N, et al. COVID-19 Infection in Men on Testosterone Replacement Therapy. J Sex Med 2020;XX:XXX-XXX.<\/p>\n
PMID:33191186 | DOI:10.1016\/j.jsxm.2020.09.013<\/p>\n
<\/p>\n
See the original post here: This article was originally published here J Sex Med. 2020 Oct 9:S1743-6095(20)30936-X Continue reading
\nCOVID-19 Infection in Men on Testosterone Replacement Therapy - DocWire News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"